We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial.
- Authors
Bielicki, Julia A.; Stöhr, Wolfgang; Barratt, Sam; Dunn, David; Naufal, Nishdha; Roland, Damian; Sturgeon, Kate; Finn, Adam; Rodriguez-Ruiz, Juan Pablo; Malhotra-Kumar, Surbhi; Powell, Colin; Faust, Saul N.; Alcock, Anastasia E.; Hall, Dani; Robinson, Gisela; Hawcutt, Daniel B.; Lyttle, Mark D.; Gibb, Diana M.; Sharland, Mike
- Abstract
<bold>Importance: </bold>The optimal dose and duration of oral amoxicillin for children with community-acquired pneumonia (CAP) are unclear.<bold>Objective: </bold>To determine whether lower-dose amoxicillin is noninferior to higher dose and whether 3-day treatment is noninferior to 7 days.<bold>Design, Setting, and Participants: </bold>Multicenter, randomized, 2 × 2 factorial noninferiority trial enrolling 824 children, aged 6 months and older, with clinically diagnosed CAP, treated with amoxicillin on discharge from emergency departments and inpatient wards of 28 hospitals in the UK and 1 in Ireland between February 2017 and April 2019, with last trial visit on May 21, 2019.<bold>Interventions: </bold>Children were randomized 1:1 to receive oral amoxicillin at a lower dose (35-50 mg/kg/d; n = 410) or higher dose (70-90 mg/kg/d; n = 404), for a shorter duration (3 days; n = 413) or a longer duration (7 days; n = 401).<bold>Main Outcomes and Measures: </bold>The primary outcome was clinically indicated antibiotic re-treatment for respiratory infection within 28 days after randomization. The noninferiority margin was 8%. Secondary outcomes included severity/duration of 9 parent-reported CAP symptoms, 3 antibiotic-related adverse events, and phenotypic resistance in colonizing Streptococcus pneumoniae isolates.<bold>Results: </bold>Of 824 participants randomized into 1 of the 4 groups, 814 received at least 1 dose of trial medication (median [IQR] age, 2.5 years [1.6-2.7]; 421 [52%] males and 393 [48%] females), and the primary outcome was available for 789 (97%). For lower vs higher dose, the primary outcome occurred in 12.6% with lower dose vs 12.4% with higher dose (difference, 0.2% [1-sided 95% CI -∞ to 4.0%]), and in 12.5% with 3-day treatment vs 12.5% with 7-day treatment (difference, 0.1% [1-sided 95% CI -∞ to 3.9]). Both groups demonstrated noninferiority with no significant interaction between dose and duration (P = .63). Of the 14 prespecified secondary end points, the only significant differences were 3-day vs 7-day treatment for cough duration (median 12 days vs 10 days; hazard ratio [HR], 1.2 [95% CI, 1.0 to 1.4]; P = .04) and sleep disturbed by cough (median, 4 days vs 4 days; HR, 1.2 [95% CI, 1.0 to 1.4]; P = .03). Among the subgroup of children with severe CAP, the primary end point occurred in 17.3% of lower-dose recipients vs 13.5% of higher-dose recipients (difference, 3.8% [1-sided 95% CI, -∞ to10%]; P value for interaction = .18) and in 16.0% with 3-day treatment vs 14.8% with 7-day treatment (difference, 1.2% [1-sided 95% CI, -∞ to 7.4%]; P value for interaction = .73).<bold>Conclusions and Relevance: </bold>Among children with CAP discharged from an emergency department or hospital ward (within 48 hours), lower-dose outpatient oral amoxicillin was noninferior to higher dose, and 3-day duration was noninferior to 7 days, with regard to need for antibiotic re-treatment. However, disease severity, treatment setting, prior antibiotics received, and acceptability of the noninferiority margin require consideration when interpreting the findings.<bold>Trial Registration: </bold>ISRCTN Identifier: ISRCTN76888927.
- Subjects
PNEUMONIA; RESEARCH; ORAL drug administration; RESEARCH methodology; MEDICAL cooperation; EVALUATION research; DRUG administration; SEVERITY of illness index; COMPARATIVE studies; RANDOMIZED controlled trials; COMMUNITY-acquired infections; REOPERATION; RESEARCH funding; ANTIBIOTICS; AMOXICILLIN; DISCHARGE planning
- Publication
JAMA: Journal of the American Medical Association, 2021, Vol 326, Issue 17, p1713
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2021.17843